P
P. V. van Dam
Publications - 4
Citations - 6
P. V. van Dam is an academic researcher. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 2, co-authored 4 publications receiving 6 citations.
Papers
More filters
Journal ArticleDOI
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
Niels J. M. Verstegen,Ruth R Hagen,J. van den Dijssel,Lisan H Kuijper,Christine Kreher,Thomas M. Ashhurst,Laura Y Kummer,Maurice Steenhuis,M. Duurland,Rivka de Jongh,Nina de Jong,Ellen van der Schoot,Amélie V. Bos,Erik Mul,Katherine Kedzierska,P. V. van Dam,Eileen W Stalman,Laura Boekel,Gertjan L Wolbink,Sander W. Tas,Joep Killestein,Zoé L.E. van Kempen,Luuk Wieske,Taco W. Kuijpers,Filip Eftimov,Theo Rispens,Marieke van Ham,Anja ten Brinke,Carolien E. van de Sandt +28 more
TL;DR: Findings indicate that SARS-CoV-2 experienced MS-OCR patients may still benefit from vaccination by inducing a broad CD8+ T cell response which has been associated with milder disease outcome.
Journal ArticleDOI
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
Zoé L.E. van Kempen,L. Hogenboom,Alyssa A. Toorop,Maurice Steenhuis,Eileen W Stalman,Laura Y Kummer,P. V. van Dam,Karien Bloem,Anja ten Brinke,S. Marieke van Ham,Ton Kuijpers,G.J. Wolbink,Floris C. Loeff,Luuk Wieske,Filip Eftimov,Theo Rispens,E. M. M. Strijbis,Joep Killestein +17 more
TL;DR: In 52 MS patients, ocrelizumab concentration at time of vaccination was found to be a good predictor for SARS-CoV-2 IgG anti-RBD titers after vaccination (comparable to B-cell count), suggesting this may be a superior biomarker to guide optimal timing for vaccinations in B- cell depleted MS patients.
Journal ArticleDOI
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
Angelina Konnova,Fien H. R. De Winter,Lisanne C Verbruggen,An Hotterbeekx,M. Berkell,Laure Anne Teuwen,Greetje Vanhoutte,B. Peeters,Silke Raats,Isolde Van der Massen,Sven De Keersmaecker,Y. Debie,M. T. Huizing,Pieter Pannus,Kristof Y. Neven,K. K. ArieÌn,Geert A. Martens,Marc Van den Bulcke,Ella Roelant,Isabelle Desombere,Sébastien Anguille,Zwi N. Berneman,M. Goossens,Herman Goossens,Surbhi Malhotra-Kumar,E. Taconelli,Timon Vandamme,Marc Peeters,P. V. van Dam,Samir Kumar-Singh +29 more
TL;DR: In this article , the authors employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune-and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine.
Journal ArticleDOI
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases
Luuk Wieske,Eileen W Stalman,P. V. van Dam,Laura Y Kummer,Maurice Steenhuis,Zoé L.E. van Kempen,Joep Killestein,Adriaan Volkers,Sander W. Tas,Laura Boekel,Gertjan Wolbink,Anneke J. van der Kooi,Joost Raaphorst,Mark Löwenberg,R. Bart Takkenberg,Geert R. D'Haens,Ph.I. Spuls,Marcel W. Bekkenk,Anne Musters,Nicoline F Post,A.L. Bosma,Marc Hilhorst,Yosta Vegting,F. J. Bemelman,Alexandre E. Voskuyl,B. Broens,A. Parra Sanchez,Cécile A. C. M. van Els,Jelle de Wit,Abraham Rutgers,Karina de Leeuw,Barbara Horváth,Jan J.G.M. Verschuuren,Annabel M. Ruiter,Lotte van Ouwerkerk,D. van der Woude,Cornelia F Allaart,Y. K. O. Teng,Pieter van Paassen,Matthias Busch,P. B. Jallah,Esther Brusse,Pieter A. van Doorn,Adája E. Baars,DirkJan Hijnen,Corine Schreurs,Willem Ludo van der Pol,H. Stephan Goedee,Sofie Keijzer,Jim B D Keijser,Olvi Cristianawati,Anja ten Brinke,Niels J. M. Verstegen,Koos H. Zwinderman,S. Marieke van Ham,Taco W. Kuijpers,Theo Rispens,Filip Eftimov +57 more
TL;DR: In this article , the authors investigated the longterm persistence of seroconversion after vaccination in patients with IMID on ISP, patients not on ISP and healthy controls, and found that ISP use was an independent determinant for the persistence of humoral responses.